Celgene Corp (CELG) 91.66 $CELG
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Final Glance: Biotechnology companies
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:20PM CDT
Bristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Midday Glance: Biotechnology companies
AP - Thu Aug 21, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
at The Street - Thu Aug 21, 10:10AM CDT
TheStreet's Jim Cramer says investors should not worry about Gilead Sciences, especially considering its low valuation.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Celgene Corporation to Present at Investor Conferences in September
Business Wire - Thu Aug 21, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Jim Cramer's 'Mad Money' Recap: Where's the Economy Headed? Check the Railroads
at The Street - Wed Aug 20, 7:08PM CDT
Union Pacific is a better indicator than interest rates or commodity prices, Cramer says.
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
Business Wire - Wed Aug 20, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene's nab(R) technology-based chemotherapy ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a Phase I study. Multiple tumor types will be explored in the study including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). The proprietary name OPDIVO has been proposed in the U.S. and other countries, but remains subject to health authority approval.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
Business Wire - Tue Aug 19, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID(R) (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins
at Investor's Business Daily - Mon Aug 18, 12:46PM CDT
Some of the fattest annual profit margins come from drugmakers whose products are meant to make people healthier. Today's Screen of the Day is Healthy Profit Margin and includes four highly rated drug stocks. Don't miss out on Jazz Pharmaceuticals...
3 Reasons Celgene Corporation's Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 11:58AM CDT
It's been an incredible three years for Celgene , as evidenced by its better-than-tripling in share price and noticeable top-line and bottom-line growth. CELG data by YCharts We saw this growth carry over into its recently reported...
Jim Cramer Answers Twitter (TWTR) Questions on Walmart (WMT), Yelp (YELP), Kinder Morgan (KMI) and More
at The Street - Mon Aug 18, 11:40AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Walmart (WMT), Yelp (YELP), Kinder Morgan Energy Partners (KMP), WhiteWave (WWAV) and more.
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Final Glance: Biotechnology companies
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:20PM CDT
Bristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Midday Glance: Biotechnology companies
AP - Thu Aug 21, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
at The Street - Thu Aug 21, 10:10AM CDT
TheStreet's Jim Cramer says investors should not worry about Gilead Sciences, especially considering its low valuation.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Celgene Corporation to Present at Investor Conferences in September
Business Wire - Thu Aug 21, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Jim Cramer's 'Mad Money' Recap: Where's the Economy Headed? Check the Railroads
at The Street - Wed Aug 20, 7:08PM CDT
Union Pacific is a better indicator than interest rates or commodity prices, Cramer says.
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
Business Wire - Wed Aug 20, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene's nab(R) technology-based chemotherapy ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a Phase I study. Multiple tumor types will be explored in the study including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer (NSCLC). The proprietary name OPDIVO has been proposed in the U.S. and other countries, but remains subject to health authority approval.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
Business Wire - Tue Aug 19, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID(R) (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins
at Investor's Business Daily - Mon Aug 18, 12:46PM CDT
Some of the fattest annual profit margins come from drugmakers whose products are meant to make people healthier. Today's Screen of the Day is Healthy Profit Margin and includes four highly rated drug stocks. Don't miss out on Jazz Pharmaceuticals...
3 Reasons Celgene Corporation's Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 11:58AM CDT
It's been an incredible three years for Celgene , as evidenced by its better-than-tripling in share price and noticeable top-line and bottom-line growth. CELG data by YCharts We saw this growth carry over into its recently reported...
Jim Cramer Answers Twitter (TWTR) Questions on Walmart (WMT), Yelp (YELP), Kinder Morgan (KMI) and More
at The Street - Mon Aug 18, 11:40AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Walmart (WMT), Yelp (YELP), Kinder Morgan Energy Partners (KMP), WhiteWave (WWAV) and more.
